Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Global Companies Move toClose Research Lab in Japan
February 5, 2007
- GE Healthcare Bio-Sciences Announces Tie-up with Effector Cell Institute
February 5, 2007
- Astellas, Kirin Tie Up for Fully Human Monoclonal Antibody
February 5, 2007
- GENERIC NEWS IN BRIEF
February 5, 2007
- Sale of Alimta to Be Limited to 400 Facilities for Now: Eli Lilly Japan
February 5, 2007
- Use of Generics Being Promotedby Spread of DPC System: Dr Chikamori
February 5, 2007
- METI to Solve Problems with Transfer Pricing Taxation System
February 5, 2007
- R&S NEWS IN BRIEF
February 5, 2007
- NPhA Leaders Committed to Solving Problem of Provisional Delivery
February 5, 2007
- AnGes MG Licenses Naglazyme from BioMarin
February 5, 2007
- BUSINESS NEWS IN BRIEF
February 5, 2007
- Toyama Starts PI Trial for Anti-Flu Drug T-705
February 5, 2007
- NEW PRODUCTS
February 5, 2007
- Fewer than Half of All Women Aware that Pill Can Boost Fertility
February 5, 2007
- Reexamination Period to Be Extended to Eight Years: PFSB
February 5, 2007
- Ajinomoto Licenses Novel Diabetes Treatment to BI
February 5, 2007
- Government-private Sector Dialogue Begins
February 5, 2007
- Kansai Bio-Cluster Is No. 4 in the World: Prof. Morishita
February 5, 2007
- PM Abe Calls For Strategic Support of Pharma Industry in Policy Speech
February 5, 2007
- Mochida Aims to Become Specialty Pharma Focused in 4 Fields
February 5, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…